Testing XH-S003 for people with PNH
Part of Blood & lymphatic clinical trials.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You weigh at least 40 kg (88 lbs) and have a BMI of 18 or above
- You have been diagnosed with PNH based on blood test results from the last 6 months
- You have not received complement inhibitor therapy before
- Your LDH level (a marker of red blood cell breakdown) is higher than normal on two separate tests during screening
- You have low hemoglobin (below 100 g/L) or have needed a blood transfusion due to PNH-related anemia during screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called SGB-9768 that may help people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down. The drug aims to control the disease and improve blood counts, which may reduce symptoms like fatigue and anemia.
This study tests an investigational drug called NM8074 that may help people with paroxysmal nocturnal hemoglobinuria (PNH) who still have symptoms despite being on Soliris. It aims to see if the new drug is safe and effective when added or when switching from Soliris.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial is testing an experimental pill called NTQ5082 for people with PNH who haven't been treated with complement inhibitors before. The goal is to see if it can improve anemia and control PNH symptoms like fatigue and blood clots.
Hear when a new PNH - Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.